Author + information
- Received July 25, 2018
- Revision received September 17, 2018
- Accepted September 25, 2018
- Published online January 7, 2019.
- Hugo De Larochellière, MDa,
- Rishi Puri, MBBS, PhDb,
- John W. Eikelboom, MBBSc and
- Josep Rodés-Cabau, MDa,∗ ()
- aDepartment of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada
- bDepartment of Cardiology, Cleveland Clinic, Cleveland, Ohio
- cPopulation Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada
- ↵∗Address for correspondence:
Dr. Josep Rodés-Cabau, Quebec Heart and Lung Institute, Laval University, 2725 Chemin Ste-Foy, Quebec City, QC G1V 4G5, Canada.
Transcatheter aortic valve replacement (TAVR) is well established for treating patients with severe aortic stenosis considered at intermediate to high surgical risk. Blood disorders such as anemia, thrombocytopenia, and acquired type 2A von Willebrand disease are relatively frequent in TAVR candidates, and multiple studies to date have highlighted their potential clinical association with mortality and/or bleeding complications post-TAVR. The present review provides an overview of various blood disorders observed pre- and post-TAVR, with special focus on their incidence, etiology, clinical association, and management.
Dr. Rodés-Cabau has received research grants from Edwards Lifesciences and Medtronic; and holds the Canadian Research Chair “Fondation Famille Jacques Larivière” for the Development of Structural Heart Disease Interventions. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received July 25, 2018.
- Revision received September 17, 2018.
- Accepted September 25, 2018.
- 2019 American College of Cardiology Foundation